Status:
RECRUITING
Multi-center MRD Registry for Inflammatory Breast Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
To collect data from participants with IBC who may have had MRD testing and may have surgery in the future.
Detailed Description
Primary Objectives -To determine the incidence of protocol specified pre-surgery MRD-positivity in IBC (assessment between completion of planned systemic therapy and surgery). Secondary Objectives ...
Eligibility Criteria
Inclusion
- Female or males ≥18 years of age with the ability to understand and sign a written
- Participants who have a clinical diagnosis of stage III or IV inflammatory breast cancer (IBC).
- Participants who are planning to have or already completed a minimum of one blood draw for Signatera testing, for which the result and clinical data can be deposited into the study database.
- Participants must be within eight months of diagnosis and have not undergone breast surgery for this diagnosis of breast cancer.
- Participants must be English-speaking.
Exclusion
- \-
Key Trial Info
Start Date :
May 5 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2032
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06966050
Start Date
May 5 2025
End Date
May 31 2032
Last Update
November 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030